PROGNOSTIC AND RESPONSE BIOMARKERS ARE THE FUTURE OF PRECISION NEPHROLOGY TRIALS
The May issue of the International Clinical Trials (ICT) magazine was published today!
In this issue is also a paper written by MultiOmic’s Business Development Associate Rebecca Cripps and it’s CEO Robert Thong addressing the question of
“what insight can recent trials give us into how molecular-level disease drivers can be used to enter into a new era of precision nephrology?”
Read the full article here.